GlassScriptPhysician profile
Ronald Aung-Din
NPI 1215987912
$38,760.11
in general payments reported to CMS, 2019-2025
69 companies · $8,695 in 2025
The $8,695 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,279 · 2020: $1,358 · 2021: $3,516 · 2022: $6,991 · 2023: $7,486 · 2024: $8,436 · 2025: $8,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25K · Education: $9.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24,607.42 |
| Education | $9.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,577.44 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Teva Pharmaceuticals USA, INC. | $2,507.49 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biogen, INC. | $1,846.87 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $1,438.36 | 2019-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $1,403.04 | 2019-2025 | |
| Lundbeck LLC | $1,313.41 | 2021-2025 | Rexulti, Vyepti |
| Ucb, INC. | $1,252.10 | 2019-2025 | Nayzilam, Zilbrysq, Briviact |
| Otsuka America Pharmaceutical, INC. | $1,178.91 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Novartis Pharmaceuticals Corporation | $1,141.04 | 2019-2025 | |
| Sk Life Science, INC. | $1,139.14 | 2021-2025 | Xcopri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,059.60 | 2022-2025 | Caplyta |
| Harmony Biosciences LLC | $1,017.64 | 2022-2025 | Wakix |
| Catalyst Pharmaceuticals, INC. | $1,017.33 | 2023-2025 | Fycompa |
| Genentech USA, INC. | $1,015.59 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $1,012.77 | 2019-2025 | Ultomiris, Soliris |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,011.39 | 2021-2025 | |
| Lilly USA, LLC | $937.19 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Axsome Therapeutics, INC. | $902.63 | 2023-2025 | Auvelity, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $848.78 | 2019-2025 | Hyqvia, Trintellix |
| Pfizer INC. | $816.31 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $722.18 | 2022-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $710.51 | 2021-2025 | Zeposia |
| Idorsia Pharmaceuticals US INC | $694.61 | 2022-2025 | Quviviq, Quviviq |
| Argenx US, INC. | $615.34 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $592.63 | 2019-2024 | Tepezza, Aimovig |
| Corium, LLC | $589.48 | 2022-2025 | Azstarys, Adlarity |
| E.R. Squibb & Sons, L.L.C. | $559.11 | 2021-2024 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $492.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $433.52 | 2020-2021 | |
| Kyowa Kirin, INC. | $400.30 | 2022-2024 | Nourianz |
| Neurelis, INC. | $399.77 | 2020-2025 | Valtoco |
| Genzyme Corporation | $332.41 | 2019-2022 | |
| Mdd US Operations, LLC | $327.98 | 2019-2025 | Qelbree |
| Tg Therapeutics, INC. | $326.08 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $323.90 | 2023-2024 | Aptiom |
| Sunovion Pharmaceuticals INC. | $323.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $315.69 | 2021-2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $245.79 | 2020-2022 | |
| Tanabe Pharma America, INC. | $242.80 | 2019-2025 | Radicava |
| Janssen Biotech, INC. | $229.62 | 2025 | |
| Supernus Pharmaceuticals, INC. | $213.03 | 2019-2025 | Qelbree, Qelbree |
| Alnylam Pharmaceuticals INC. | $189.49 | 2024-2025 | Amvuttra, Onpattro |
| Azurity Pharmaceuticals, INC. | $177.94 | 2023-2025 | Horizant, Horizant |
| Acorda Therapeutics, INC | $156.21 | 2019-2023 | Inbrija, Ampyra |
| Janssen Pharmaceuticals, INC | $149.12 | 2022-2025 | Spravato, Ponvory |
| Insightec,INC | $136.70 | 2023 | Exablate |
| Abbott Laboratories | $130.52 | 2024 | Infinity |
| Banner Life Sciences, LLC | $130.40 | 2022-2023 | |
| Octapharma USA, INC. | $123.32 | 2024 | Panzyga |
| Vanda Pharmaceuticals INC. | $118.70 | 2025 | Fanapt, Ponvory |
| Bausch Health US, LLC | $115.64 | 2023-2025 | Aplenzin, Wellbutrin |
| Greenwich Biosciences, INC. | $104.04 | 2019 | |
| Impel Pharmaceuticals INC. | $99.06 | 2022 | |
| Upsher-Smith Laboratories LLC | $94.51 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $90.34 | 2019 | |
| Merz Pharmaceuticals, LLC | $57.77 | 2024-2025 | Inbrija, Xeomin |
| Grt US Holding, INC. | $53.75 | 2022 | |
| Impel Pharmaceuticals LLC | $48.05 | 2025 | Trudhesa |
| Allergan, INC. | $47.30 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.45 | 2019 | |
| Ge Healthcare | $23.46 | 2023 | |
| Nevro Corp. | $22.55 | 2022 | |
| Zyla Life Sciences, INC. | $22.52 | 2019 | |
| Aucta Pharmaceuticals, INC. | $22.35 | 2025 | Motpoly Xr |
| Assertio Therapeutics, INC. | $21.26 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.70 | 2022 | |
| C2n Diagnostics, LLC | $15.92 | 2025 | Precivityad2 |
| Zogenix INC. | $14.43 | 2021 | |
| Neuronetics, INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Aung-Din listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.